Adalimumab-Induced Isolated Peritoneal Tuberculosis

The therapeutic approach to immune-mediated diseases including Crohn’s disease has dramatically improved with the introduction of immunomodulators such as anti-tumor necrosis factor (TNF). However, its use is not complication-free, and since its introduction, a growing number of opportunistic infections is being reported in patients under treatment despite all preventive measures taken. Herein, we report a case of adalimumab-induced isolated peritoneal tuberculosis.